{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:26:52Z","timestamp":1790908012369,"version":"4.1.0"},"reference-count":3,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2001]]},"abstract":"<jats:p>&lt;i&gt;Objective:&lt;\/i&gt; Several schedules with variable doses of intracavitary interferon have been proposed for the management of metastatic peritoneal effusions. This prospective pilot study evaluated the efficacy of a standardized schedule of intraperitoneal interferon \u03b1&lt;sub&gt;2b&lt;\/sub&gt;. &lt;i&gt;Methods:&lt;\/i&gt; In 41 cancer patients with malignant ascites a 9-french intraperitoneal catheter was placed under sonographic guidance, and ascites was drained until abdominal ultrasound showed complete absence of effusion. Interferon \u03b1&lt;sub&gt;2b&lt;\/sub&gt;, 6 or 9 million units (body weight \u2264 or &gt;50 kg, respectively), was then administered via the tube, which was clamped for 6\u00a0h. 6 courses were given at 4-day intervals. In comparison with pretreatment levels, the 30-day response was classified as complete (CR) = no fluid recurrence, partial (PR) = fluid recurrence &lt;50% and no response (NR) = &gt;50%. Responders were monitored until fluid recurrence requiring paracentesis. &lt;i&gt;Results:&lt;\/i&gt; 12 patients had CR, 15 PR, 14 NR. Global response (GR) was 65.9%. In ovarian cancer, GR was 75% and was not influenced by the quantity of the pretreatment daily fluid production. In the other cancers, a pretreatment fluid production \u2264500 ml\/day was associated with a significantly higher response (p &lt; 0.05). Patients not showing response within the first 3 courses did not respond after the next courses. 60-day GR was 41.5%, 90-day GR was 26.8%. The mean time to fluid reaccumulation was 70.5 \u00b1 75.3 versus 11.4 \u00b1 4.4 days before treatment (p &lt; 0.001). The survival of responders was 38\u2013394 days (mean 131), and the average duration of response was 101 days. &lt;i&gt;Conclusion:&lt;\/i&gt; This protocol could be reasonably applied to ovarian cancer patients and to patients with other cancers having a fluid production of \u2264500 ml\/day, and it should be stopped if no response is observed after 3 courses of treatment.<\/jats:p>","DOI":"10.1159\/000055374","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T19:06:20Z","timestamp":1050433580000},"page":"192-196","source":"Crossref","is-referenced-by-count":30,"title":["Evaluation of a Standardized Protocol of Intracavitary Recombinant Interferon Alpha-2b in the Palliative Treatment of Malignant Peritoneal Effusions"],"prefix":"10.1159","volume":"61","author":[{"given":"Sergio","family":"Sartori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Tassinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Trevisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Abbasciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Malacarne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2001,9,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050407"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1996.0040"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690421"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/55374","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/55374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:37:40Z","timestamp":1745469460000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000055374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":3,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2001,9,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000055374","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001]]}}}